Publications by authors named "S Postel-Vinay"
Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.
View Article and Find Full Text PDFArticle Synopsis
- Desmoplastic small round cell tumor (DSRCT) is an aggressive form of cancer linked to a specific genetic factor called EWS-WT1, and treatment options have not improved significantly in over 20 years.
- Researchers conducted a comprehensive drug sensitivity test on DSRCT cells and found that they respond well to PARP and ATR inhibitors, both alone and in combination, showcasing these treatments across various models.
- The study reveals that the combination of these inhibitors causes significant DNA damage and activates immune responses, suggesting that targeting EWS-WT1 could be an effective strategy in treating DSRCT.
Background: Early-phases clinical trials (Phases 1 and 2) have evolved from a traditional assessment of toxicity to an adaptive approach based on patients' medical needs and access to effective new therapies. The global risks, benefits, and relevance of early-phases clinical trials participation for patients with hematological malignancies remain poorly evaluated.
Patients And Methods: All early-phases clinical trials participations for patients with hematological malignancies, from 2008 to 2023, in a tertiary academic center in Europe, were reviewed.
Article Synopsis
- AMG 193 is a drug that targets tumor cells lacking the MTAP gene, which is deleted in approximately 10%-15% of solid tumors, and has shown promise in selectively killing these cancer cells through synthetic lethality.* -
- The phase I clinical study involved 80 patients with advanced solid tumors, testing varying doses of AMG 193 to assess safety, tolerability, and preliminary effectiveness; common side effects included nausea, fatigue, and vomiting.* -
- Results indicated a maximum tolerated dose of 1200 mg, with a 21.4% objective response rate observed in patients receiving effective doses, suggesting activity against multiple tumor types including lung and pancreatic cancers.*
Article Synopsis
- Patients with advanced tumors in phase I trials often have strong treatment hopes but limited options; local ablative stereotactic radiation therapy (SRT) can help manage disease progression when oligoprogressive resistance occurs.* -
- A study analyzed 42 patients receiving SRT for oligoprogressive lesions, finding that SRT significantly extended progression-free survival (7.1 months) and time to the next treatment (12.8 months), with no severe toxicities reported.* -
- The findings suggest that tumor characteristics, like aggressiveness and clonal diversity, can help distinguish between patients needing different management strategies after SRT, potentially enhancing treatment outcomes.*